|
1
|
Daly CJ and McGrath JC: Previously
unsuspected widespread cellular and tissue distribution of
β-adrenoceptors and its relevance to drug action. Trends Pharmacol
Sci. 32:219–226. 2011.PubMed/NCBI
|
|
2
|
Drell TL IV, Joseph J, Lang K, Niggemann
B, Zaenker KS and Entschladen F: Effects of neurotransmitters on
the chemokinesis and chemotaxis of MDA-MB-468 human breast
carcinoma cells. Breast Cancer Res Treat. 80:63–70. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Masur K, Niggemann B, Zanker KS and
Entschladen F: Norepinephrine-induced migration of SW 480 colon
carcinoma cells is inhibited by beta-blockers. Cancer Res.
61:2866–2869. 2001.PubMed/NCBI
|
|
4
|
Palm D, Lang K, Niggemann B, Drell TL IV,
Masur K, Zaenker KS and Entschladen F: The norepinephrine-driven
metastasis development of PC-3 human prostate cancer cells in
BALB/c nude mice is inhibited by beta-blockers. Int J Cancer.
118:2744–2749. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Wadei HA, Al-Wadei MH and Schuller HM:
Prevention of pancreatic cancer by the beta-blocker propranolol.
Anticancer Drugs. 20:477–482. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sood AK, Bhatty R, Kamat AA, et al: Stress
hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res.
12:369–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang EV, Kim SJ, Donovan EL, et al:
Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human
melanoma tumor cell lines: implications for stress-related
enhancement of tumor progression. Brain Behav Immun. 23:267–275.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schuller HM: Is cancer triggered by
altered signalling of nicotinic acetylcholine receptors? Nat Rev
Cancer. 9:195–205. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sloan EK, Priceman SJ, Cox BF, et al: The
sympathetic nervous system induces a metastatic switch in primary
breast cancer. Cancer Res. 70:7042–7052. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Algazi M, Plu-Bureau G, Flahault A, Dondon
MG and Lê MG: Could treatments with beta-blockers be associated
with a reduction in cancer risk? Rev Epidemiol Sante Publique.
52:53–65. 2004.(In French).
|
|
11
|
Perron L, Bairati I, Harel F and Meyer F:
Antihypertensive drug use and the risk of prostate cancer (Canada).
Cancer Causes Control. 15:535–541. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Powe DG, Voss MJ, Zänker KS, Habashy HO,
Green AR, Ellis IO and Entschladen F: Beta-blocker drug therapy
reduces secondary cancer formation in breast cancer and improves
cancer specific survival. Oncotarget. 1:628–638. 2010.PubMed/NCBI
|
|
13
|
Ganz PA, Habel LA, Weltzien EK, Caan BJ
and Cole SW: Examining the influence of beta blockers and ACE
inhibitors on the risk for breast cancer recurrence: results from
the LACE cohort. Breast Cancer Res Treat. 129:546–556.
2011.PubMed/NCBI
|
|
14
|
Barron TI, Connolly RM, Sharp L, Bennett K
and Visvanathan K: Beta blockers and breast cancer mortality: a
population-based study. J Clin Oncol. 29:2635–2644. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Melhem-Bertrandt A, Chavez-Macgregor M,
Lei X, et al: Beta-blocker use is associated with improved
relapse-free survival in patients with triple-negative breast
cancer. J Clin Oncol. 29:2645–2652. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De Giorgi V, Grazzini M, Gandini S,
Benemei S, Lotti T, Marchionni N and Geppetti P: Treatment with
β-blockers and reduced disease progression in patients with thick
melanoma. Arch Intern Med. 171:779–781. 2011.
|
|
17
|
Lemeshow S, Sørensen HT, Phillips G, et
al: β-Blockers and survival among Danish patients with malignant
melanoma: a population-based cohort study. Cancer Epidemiol
Biomarkers Prev. 20:2273–2279. 2011.
|
|
18
|
Park SY, Kang JH, Jeong KJ, et al:
Norepinephrine induces VEGF expression and angiogenesis by a
hypoxia-inducible factor-1α protein-dependent mechanism. Int J
Cancer. 128:2306–2316. 2011.PubMed/NCBI
|
|
19
|
Magnoni MS, Frattola L, Piolti R, Govoni
S, Kobayashi H and Trabucchi M: Glial brain tumors lack
microvascular adrenergic receptors. Eur Neurol. 28:27–29. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ruck A, Millns P, Kendall DA and Hill SJ:
Expression of beta 2-adrenoceptors mediating cyclic AMP
accumulation in astroglial and neuronal cell lines derived from the
rat CNS. Biochem Pharmacol. 40:2371–2375. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sokołowska P and Nowak JZ: Constitutive
activity of beta-adrenergic receptors in C6 glioma cells. Pharmacol
Rep. 57:659–663. 2005.PubMed/NCBI
|
|
22
|
Lung HL, Shan SW, Tsang D and Leung KN:
Tumor necrosis factor-alpha mediates the proliferation of rat C6
glioma cells via beta-adrenergic receptors. J Neuroimmunol.
166:102–112. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Annabi B, Lachambre MP, Plouffe K,
Moumdjian R and Béliveau R: Propranolol adrenergic blockade
inhibits human brain endothelial cells tubulogenesis and matrix
metalloproteinase-9 secretion. Pharmacol Res. 60:438–445. 2009.
View Article : Google Scholar
|
|
24
|
Annabi B, Vaillancourt-Jean E, Weil AG and
Béliveau R: Pharmacological targeting of β-adrenergic receptor
functions abrogates NF-κB signaling and MMP-9 secretion in
medulloblastoma cells. Onco Targets Ther. 3:219–226. 2010.
|
|
25
|
Toll L, Jimenez L, Waleh N, et al:
{Beta}2-adrenergic receptor agonists inhibit the proliferation of
1321N1 astrocytoma cells. J Pharmacol Exp Ther. 336:524–532.
2011.
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chakroborty D, Sarkar C, Basu B, Dasgupta
PS and Basu S: Catecholamines regulate tumor angiogenesis. Cancer
Res. 69:3727–3730. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang D, Ma Q, Shen S and Hu H: Inhibition
of pancreatic cancer cell proliferation by propranolol occurs
through apoptosis induction: the study of beta-adrenoceptor
antagonist’s anticancer effect in pancreatic cancer cell. Pancreas.
38:94–100. 2009.PubMed/NCBI
|
|
29
|
Pasquier E, Ciccolini J, Carre M, et al:
Propranolol potentiates the anti-angiogenic effects and anti-tumor
efficacy of chemotherapy agents: implication in breast cancer
treatment. Oncotarget. 2:797–809. 2011.PubMed/NCBI
|
|
30
|
Entschladen F, Drell TL IV, Lang K, Joseph
J and Zaenker KS: Tumour-cell migration, invasion, and metastasis:
navigation by neurotransmitters. Lancet Oncol. 5:254–258. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Entschladen F, Drell TL IV, Lang K, Joseph
J and Zaenker KS: Neurotransmitters and chemokines regulate tumor
cell migration: potential for a new pharmacological approach to
inhibit invasion and metastasis development. Curr Pharm Des.
11:403–411. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Diaz E, Karlan B, Cass I, Walsh C and Li
A: Impact of beta blockers on epithelial ovarian cancer survival.
Gynecol Oncol. 120(Suppl 1): S362011. View Article : Google Scholar
|
|
33
|
Shakhar G and Ben-Eliyahu S: In vivo
beta-adrenergic stimulation suppresses natural killer activity and
compromises resistance to tumor metastasis in rats. J Immunol.
160:3251–3258. 1998.PubMed/NCBI
|
|
34
|
Lakka SS, Gondi CS and Rao JS: Proteases
and glioma angiogenesis. Brain Pathol. 15:327–341. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ristori C, Filippi L, Dal Monte M, et al:
Role of the adrenergic system in a mouse model of oxygen-induced
retinopathy: antiangiogenic effects of beta-adrenoreceptor
blockade. Invest Ophthalmol Vis Sci. 52:155–170. 2011. View Article : Google Scholar : PubMed/NCBI
|
